share_log

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Elicio Therapeutics將在2024年度海豐國際年會和Stand Up to Cancer(SU2C)創新峯會上展示臨床數據
GlobeNewswire ·  10/31 20:30

Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study

在海豐國際(SITC)舉行的海報展示中,將重點展示來自AMPLIFY-7P階段1研究的延長後續數據

Oral presentation at SU2C Innovation Summit to highlight data from AMPLIFY-7P and AMPLIFY-201 Phase 1 studies

在Stand Up To Cancer創新峯會上的口頭報告中,將重點展示來自AMPLIFY-7P和AMPLIFY-201階段1研究的數據

BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced two upcoming presentations in November.

2024年10月31日,波士頓(環球新聞社)——臨床階段的生物技術公司Elicio Therapeutics, Inc.(納斯達克股票代碼: ELTX,Elicio Therapeutics或Elicio),宣佈了即將在11月舉行的兩場演講

The first presentation will take place at the upcoming Society for Immunotherapy of Cancer ("SITC") 39th Annual Meeting, being held November 6-10, 2024, in Houston, Texas. The presentation will include updated T cell and Disease-Free Survival ("DFS") data from the ongoing AMPLIFY-7P Phase 1 clinical trial (NCT05726864) of ELI-002, an Amphiphile ("AMP") cancer vaccine that targets KRAS-mutant tumors. The Phase 2 portion of AMPLIFY-7P is ongoing in patients with pancreatic cancer with enrollment expected to complete in Q4 2024.

第一場演講將於2024年11月6日至10日在德克薩斯州休斯敦舉行的即將進行的海豐國際(SITC)第39屆年會上舉行。此次演講將包括來自進行中的ELI-002的AMPLIFY-7P階段1臨床試驗(NCT05726864)的更新t細胞和無病生存(DFS)數據,這是一種針對KRAS突變腫瘤的兩性分子脂質疫苗(「AMP」)。AMPLIFY-7P的第2階段正在進行中,預計於2024年第四季度完成胰腺癌患者的納入

Poster Presentation Details

海報展示詳細信息

Title: AMPLIFY-7P Phase 1a: Lymph node-targeted amphiphile therapeutic cancer vaccine in patients with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer (Abstract #1473)

標題: AMPLIFY-7P 第1a期: 針對高復發風險KRAS突變胰腺導管腺癌和結直腸癌患者的淋巴結靶向兩性治療癌症疫苗 (摘要 #1473)

Session Date and Time: Friday, November 8, 2024, 12:15-1:45 p.m. ET

會議日期和時間: 2024年11月8日星期五,下午12:15-1:45 (美國東部時間)

The second presentation will take place at the Stand Up To Cancer ("SU2C") Innovation Summit: Cancer Detection and Vaccines, being held November 4, 2024, in New York. Peter Demuth, Ph.D., Executive Vice President, Chief Scientific Officer of Elicio Therapeutics, will present updates on the AMP platform and data from the AMPLIFY-7P (NCT05726864) and AMPLIFY-201 (NCT04853017) Phase 1 trials.

第二次報告將在「抗癌大賽」(「SU2C」)創新峯會: 癌症檢測和疫苗上進行,該峯會將於2024年11月4日在紐約舉行。Elicio Therapeutics的執行副總裁,首席科學官Peter Demuth博士將介紹AMP平台的最新進展和AMPLIFY-7P (NCT05726864) 和AMPLIFY-201 (NCT04853017) 第1期試驗的數據。

Oral Presentation Details

口頭報告詳情

Title: Targeting Cancer Vaccination to the Lymph Nodes to Promote Anti-tumor Immunity

標題: 將癌症疫苗靶向淋巴結以促進抗腫瘤免疫

Session Date and Time: Monday, November 4, 2024, 2:45 p.m. ET

會話日期和時間: 2024年11月4日,美東時間下午2:45

About Elicio Therapeutics

關於Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system's cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes' natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. Elicio's R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit .

Elicio Therapeutics, Inc.(納斯達克交易所股票代碼:ELTX)是一家臨床階段的生物技術公司,致力於推進一系列面向最具侵略性癌症的新型淋巴結靶向免疫療法。通過結合免疫學和免疫療法方面的專業知識,Elicio正在利用AMP技術,將治療載荷直接傳遞至淋巴結,目的是增強免疫系統抗癌能力。通過將癌症免疫療法定位於免疫反應的核心,AMP旨在優化淋巴結天然教育、激活和放大癌症特異T細胞的能力,這對於識別和清除腫瘤細胞至關重要。AMP被設計用於同步在這些高效位點激活免疫力,旨在增強免疫反應的強度、效力、質量和持久性,以驅動抗腫瘤活動。Elicio的研發管線包括現貨治療癌症疫苗ELI-002(針對mKRAS驅動的癌症),以及ELI-007和ELI-008(分別針對BRAF驅動的癌症和p53熱點突變)。欲了解更多信息,請訪問。

About ELI-002

關於ELI-002

Our lead product candidate, ELI-002, is a structurally novel investigational Amphiphile ("AMP") cancer vaccine that targets cancers that are driven by mutations in the KRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with our AMP technology consisting of AMP-modified mutant KRAS peptide antigens and an AMP-modified CpG adjuvant that is available as an off-the-shelf subcutaneous administration.

我們的主導產品候選藥ELI-002是一種結構新穎的調查性兩性分子("AMP")癌症疫苗,針對由KRAS基因突變驅動的癌症-許多人類癌症的主要推動因素。ELI-002由兩個強大的元件組成,使用我們的AMP技術構建,包括AMP修飾的突變KRAS多肽抗原和AMP修飾的CpG佐劑,可作爲即用型皮下給藥。

ELI-002 2P (2-peptide formulation) is currently being studied in an ongoing Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy (NCT04853017). ELI-002 7P (7-peptide formulation) is currently being studied in a Phase 1/2 (AMPLIFY-7P) trial in patients with mKRAS-driven pancreatic cancer (NCT05726864). The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present in 25% of all solid tumors, thereby increasing the potential patient population for ELI-002.

ELI-002 2P(2肽配方)目前正在進行一項進行中的1期(AMPLIFY-201)試驗,用於研究在進行手術和化療後,具有高復發風險的mKRAS驅動實體腫瘤患者(NCT04853017)。ELI-002 7P(7肽配方)目前正在進行一項1/2期(AMPLIFY-7P)試驗,用於研究具有mKRAS驅動的胰腺癌患者(NCT05726864)。ELI-002 7P配方旨在提供對25%所有實體瘤中存在的七種最常見KRAS突變的免疫應答覆蓋,從而擴大ELI-002的潛在患者群。

About the Amphiphile Platform

關於Amphiphile Platform 我們的專有Amphiphile或AMP平台可將調查性免疫療法直接傳遞到免疫系統的「大腦中心」——淋巴結。我們認爲,針對疾病特異性抗原,佐劑和其他免疫調節劑的此特定部位傳遞可以有效地教育,激活和放大關鍵免疫細胞,從而潛在地誘導和維持治療許多疾病所需的強大適應性免疫性。在臨床前模型中,我們觀察到淋巴結特定的參與驅動治療免疫反應增加了免疫細胞功能和持久性。我們認爲,與基於臨床前研究不涉及淋巴結的免疫療法相比,我們的AMP淋巴結靶向方法將產生更優越的臨床療效。

Our proprietary AMP platform delivers investigational immunotherapeutics directly to the "brain center" of the immune system – the lymph nodes. We believe this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. We believe our AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based upon preclinical studies.

我們的獨有AMP平台直接將調查性免疫治療藥物輸送至免疫系統的「大腦中樞」——淋巴結。我們相信將疾病特異性抗原、佐劑和其他免疫調節物質定點輸送至該部位,可能有效地教育、激活和增強關鍵免疫細胞,潛在地誘導並保持強效適應性免疫,從而治療許多疾病。在臨床前模型中,我們觀察到與淋巴結特異性的參與推動治療性免疫反應的增加程度、功能性和持久性。我們認爲我們的AMP淋巴結靶向方法將產生比不涉及淋巴結的免疫治療方法更優越的臨床效益,據臨床前研究顯示。

Our AMP platform, originally developed at the Massachusetts Institute of Technology has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships.

我們的AMP平台最初是在麻省理工學院開發的,其在癌症領域具有廣泛的潛力,通過內部活動,執照安排或開展合作和夥伴關係來推進多項開發計劃。

The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the bloodstream, as it travels to lymphatic tissue. In preclinical models, we have observed lymph node-specific engagement driving immune responses of increased magnitude, function and durability.

通過鎖定血液中的蛋白質白蛋白並將其傳遞到淋巴組織,我們已經證明了AMP平台可以將免疫治療藥物直接傳遞到淋巴結。在臨床前模型中,我們觀察到淋巴結特異性參與驅動免疫反應的幅度,功能和持久性增加。

Cautionary Note on Forward-Looking Statements

前瞻性聲明的警示說明

Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding Elicio's planned clinical programs, including planned clinical trials, the potential of Elicio's product candidates, the expected participation and presentation at upcoming conferences and medical meetings, and other statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio's financial condition, including its anticipated cash runway and ability to obtain the funding necessary to advance the development of ELI-002 and any other future product candidates, and Elicio's ability to continue as a going concern; Elicio's plans to develop and commercialize its product candidates, including ELI-002; the timing of initiation of Elicio's planned clinical trials; the timing of the availability of data from Elicio's clinical trials, including updated T cell and DFS data from the ongoing AMPLIFY-7P Phase 1 clinical trial of ELI-002; the timing of any planned investigational new drug application or new drug application; Elicio's plans to research, develop and commercialize its current and future product candidates; and Elicio's estimates regarding future revenue, expenses, capital requirements and need for additional financing.

本通訊中包含的有關非歷史事實的事項的某些聲明屬於《1934年證券交易法》第21E條修正案及1995年《私人證券訴訟改革法》(PSLRA)規定的前瞻性聲明。這些包括有關Elicio計劃的臨床項目,包括計劃的臨床試驗,Elicio產品候選者的潛力,預計參加和在即將舉行的會議和醫學會議上發表演講等相關聲明,以及有關管理層意圖、計劃、信念、期望或未來預測的其他聲明,因此,請注意不要過分依賴這些聲明。無法保證任何前瞻性聲明,並且實際結果可能大不相同。Elicio不承擔公開更新任何前瞻性聲明的義務,除非根據法律要求。我們使用" anticipate," "believe," "plan," "expect," "project," "future," "intend," "may," "will," "should," "could," "estimate," "predict," "potential," "continue," "guidance," 等詞彙來識別這些意圖受到PSLRA庇護條款覆蓋的前瞻性聲明。這些前瞻性聲明基於我們的預期並涉及風險和不確定性;因此,實際結果可能與陳述中所述的相去甚遠,原因有許多,包括但不限於Elicio的財務狀況,包括其預期的現金維持期限和取得推動ELI-002及任何其他未來產品候選者發展所需的資金的能力,以及Elicio繼續作爲持續經營的能力;Elicio的計劃開發和商業化其產品候選者,包括ELI-002;Elicio計劃啓動其計劃臨床試驗的時間;Elicio的臨床試驗結果數據的可用時間,包括ELI-002正在進行的AMPLIFY-7P 1期臨床試驗中更新的T細胞和DFS數據的時間;任何計劃的新藥投治試驗申請或新藥申請的時間;Elicio研究、開發和商業化其當前和未來產品候選者的計劃;以及Elicio對未來營業收入、費用、資本需求和融資需求的估計。

New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks are more fully discussed in the Annual Report on Form 10-K filed with the SEC on March 29, 2024, as amended on April 29, 2024, under the heading "Risk Factors", and any subsequent reports and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.

新因素時常出現,我們無法預測所有這些因素,也無法評估每個因素對業務的影響或任何因素或因素組合可能導致實際結果與任何前瞻性陳述中所包含結果有實質性差異的程度。這些風險在2024年3月29日提交給SEC的10-k表格修訂於2024年4月29日的年度報告中有更詳細的討論,在標題爲「風險因素」的章節下列出,並會不時根據SEC的要求提交的後續報告和其他文件進行更新。本發佈中包含的前瞻性陳述是基於Elicio截止本發佈日期的信息。Elicio不承擔任何義務更新這些前瞻性陳述以反映本發佈日期後發生的事件或情況,除非法律要求。

Investor Relations Contact

投資者關係聯繫人

Carlo Tanzi, Ph.D.
ctanzi@kendallir.com

肯達爾投資者關係公司
ctanzi@kendallir.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論